Tumour necrosis factor-α antagonists and their therapeutic applications

Bibliography

• MARRIOTT JB, WESTBY M, DALGLEISH AG: Therapeutic potential of TNF-a inhibitors old and new. Drug Disc. Today (1997) 2(7):273–282.
   Web of Science ®Google Scholar
• •Overview of therapeutic potential of different classes of TNF-a inhibitors.
   Google Scholar
• WARE CF, VANARSDALE TL, CROWE PD, BROWNING JL: The ligands and receptors of the lymphotoxin system. Curr. Top. Microbiol. Immunol. (1995) 198:175–218.
   PubMedGoogle Scholar
• VANDENABEELE P, DECLERCQ W, BEYAERT R, FIERS W: Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. (1995) 5:392–399.
   PubMed Web of Science ®Google Scholar
• •Good review of receptor function.
   Google Scholar
• BJORNEBERG F, LANTZ M, OLSSON I, GULLBERG U: Mechanisms involved in the processing of the p55 and the p75 tumor necrosis factor (TNF) receptors to solu-ble receptor forms. Lymphokine Cytokine Res. (1994) 13 (3) :203–211.
   PubMedGoogle Scholar
• STEWART RJ, MARSDEN PA: Biologic control of the tu-mor necrosis factor and interleukin-1 signaling cas-cade. Am. J. Kidney Dis. (1995) 25(6):954–966.
   PubMed Web of Science ®Google Scholar
• SUTO MJ, RANSOME LI Novel approaches for the treat-ment of inflammatory diseases: inhibitors of NF-KB and AP-1. Curr. Pharm. Design (1997) 3:515–528.
   Web of Science ®Google Scholar
• •Concise review of NF-KB, its role in disease, and known inhibitors.
   Google Scholar
• BAEUERLE PA, BAICHVVAL VR: NF-KB as a frequent target for immunosuppressive and anti-inflammatory mole-cules. Adv. Immunol. (1997) 65:111–137.
   PubMed Web of Science ®Google Scholar
• AGGARWAL BB, NATARAJAN K: Tumour necrosis factors: developments during the last decade. Eur. Cyto-kine Netw. (1996) 7(2) :93–124.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of the nature and mechanisms of ac-tion of the TNF family.
   Google Scholar
• SINGH S, AGGARWAL BB: Protein-tyrosine phos-phatase inhibitors block tumor necrosis factor-dependent activation of the nuclear transcription fac-tor NF-03. J. Biol. Chem. (1995) 270(1010631–10639.
   Web of Science ®Google Scholar
• MANIATIS T: Catalysis by a multiprotein 1KB kinase complex. Science (1997) 278:818–819.
   PubMed Web of Science ®Google Scholar
• •Discussion of the activation pathway of NF-icB.
   Google Scholar
• MCWHINNEY CD, DUDLEY MW, BOWLIN TL et al: Activa-tion of adenosine A3 receptors on macrophages inhib-its tumor necrosis factor-a. Eur. J. Pharmacol. (1996) 310:209–216.
   PubMed Web of Science ®Google Scholar
• SEKUT L, CONNOLLY KM: Pathophysiology and regula-tion of TNF-a in inflammation. Drug News Perspect (1996) 9(5):261–269.
   Web of Science ®Google Scholar
• ARMSTRONG AM, GARDINER KR, KIRK SJ, HALLIDAY MI,ROWLANDS BJ: Tumour necrosis factor and inflamma-tory bowel disease. Br. J. Surg. (1997) 84(8):1051–1058.
   PubMedGoogle Scholar
• FELDMAN M, BRENNAN FM, ELLIOTT M, KATSIKIS P, MAINI RN: TNFa as a therapeutic target in rheumatoid arthritis. Circ. Shock (1994) 43:179–184.
   PubMedGoogle Scholar
• YOSHIDA S, ONO M, SHONO T et al: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol. Cell. Biol. (1997) 17 (7):4015–4023.
   PubMed Web of Science ®Google Scholar
• MANOLAGAS SC: Role of cytokines in bone resorption. Bone (1995) 17(2) Suppl.: 63S–67S.
   Google Scholar
• ROODMAN GD: Advances in bone biology: the osteo-clast. Endocr. Rev. (1996) 17(4):308–332.
   PubMed Web of Science ®Google Scholar
• OZAKI K, TAKEDA H, IWAHASHI H, KITANO S, HA-NAZAWA S: NF-03 inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit bone resorption by these cells. FEBS Lett. (1997) 410:297–300.
   PubMed Web of Science ®Google Scholar
• UREN AG, VAUX DL: Molecular and clinical aspects of apoptosis. Pharmacol. Ther. (1996) 72(1):37–50.
   PubMed Web of Science ®Google Scholar
• •Good review of apoptosis.
   Google Scholar
• KARSAN A, HARLAN JM: Modulation of endothelial cell apoptosis: mechanisms and pathophysiological roles. Atheroscler. Thromb. (1996) 3(2):75–80.
   Google Scholar
• FEUERSTEIN G, RUFFOLO RR Jr, YUE T-L: Apoptosis and congestive heart failure. Trends Cardiovasc. Med. (1997) 7(7)249–255.
   Google Scholar
• MARTINOU J-C, SADOUL R: ICE-like proteases execute the neuronal death program. Curr. Opin. Neurobiol (1996) 6(5):609–614.
   PubMed Web of Science ®Google Scholar
• DAVIDSEN SK, SUMMERS JB: Inhibitors of TNFa synthe-sis. Exp. Opin. Ther. Patents (1995) 5(10):1087–1100.
   Google Scholar
• •Account of small-molecule inhibitors of TNF-a production.
   Google Scholar
• Inhibitors of TNF production. Exp. Opin. Ther. Patents (1994) 4(5):551–554.
   Google Scholar
• LEE JC, PRABHAKAR U, GRISWOLD DE et al. Low-molecular-weight TNF biosynthesis inhibitors: strate-gies and prospectives. Circ. Shock (1995) 44:97–103.
   Google Scholar
• DE BRITO FB, SOUNESS JE, WARNE PJ: Type 4 phos-phodiesterase inhibitors and their potential in the treatment of inflammatory disease. In: Emerging Drugs (Volume 2). WC Bowman, JD Fitzgerald, JB Taylor (Eds.), Ashley Publications Ltd., London, UK (1997):259–268.
   Google Scholar
• •Informative review of the potential of PDE4 inhibitors and development compounds.
   Google Scholar
• NICHOLSON CD, SHAHID M: Inhibitors of cyclic nucleo-tide phosphodiesterase isoenzymes - their potential utility in the therapy of asthma. Pulmon. Pharmacol (1994) 7(0:1–17.
   PubMedGoogle Scholar
• PALACIOS JM, BELETA J, SEGARRA V: Second messenger systems as targets for new therapeutic agents: focus on selective phosphodiesterase inhibitors. Farmaco (1995) 50(12):819–827.
   PubMedGoogle Scholar
• FISHER DA, SMITH JF, PILLAR JS, ST. DENIS SH, CHENG JB: Isolation and characterization of PDE8A, a novel hu-man cAMP-specific phosphodiesterase. Biochem. Bio-phys. Res. Commun. (1998) 246:570–577.
   PubMed Web of Science ®Google Scholar
• BEAVO JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. (1995) 75(4):725–748.
   PubMed Web of Science ®Google Scholar
• TEIXEIRA MM, GRISTWOOD RW, COOPER N, HELLEWELLPG: Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharm. Sci. (1997) 18:164–171.
   Google Scholar
• SOUNESS JE, GRIFFIN M, MASLEN C et al.: Evidence thatcyclic AMP phosphodiesterase inhibitors suppress TNFa generation from human monocytes by interact-ing with a low-affinity' phosphodiesterase 4 con-former. Br. J. Pharmacol. (1996) 118:649–658.
   PubMed Web of Science ®Google Scholar
• SIEGMUND B, EIGLER A, MOELLER J et al: Suppression oftumor necrosis factor-a production by interleukin-10 11.GOTO M. YAMADA K. KATAYAMA K-I. TANAKA I: Inhibi- GOTO M, YAMADA K, KATAYAMA K-I, TANAKA I: Inhibi-tory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-a generation, on acti-vation of nuclear factor-KB. Mol. Pharm. (1996) 49:860-873. is enhanced by cAMP-elevating agents. Eur. J. Pharma-col. (1997) 321:231–239.
   Google Scholar
• YOSHIMURA T, KURITA C, NAGAO T et al: Effects of cAMP-phosphodiesterase isozyme inhibitor on cyto-kine production by lipopolysaccharide-stimulated hu-man peripheral blood mononuclear cells. Gen. Pharmacol. (1997) 29(4):633–638.
   PubMedGoogle Scholar
• TANNENBAUM CA, HAMILTON TS: Lipopolysaccharide-induced gene expression in murine peritoneal macro-phages is selectively suppressed by agents that elevate intracellular cAMP. j Imrnunol. (1989) 142(4)1274–1280.
   Google Scholar
• SCHWABE U, MIYAKE M, OHGA Y, DALY JW: 4-(3-Cyclopentyloxy-4- methoxypheny1)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3',5'-monophosphate phosphodiesterases in ho-mogenates and tissue slices from rat brain. Mol. Phar-macol. (1976) 12(6):900–910.
   PubMed Web of Science ®Google Scholar
• ANGEL JB, SAGET BM, WALSH SP et al.: Rolipram, a spe-cific Type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication. AIDS (1995) 9:1137–1144.
   PubMed Web of Science ®Google Scholar
• KLAUSNER JD, FREEDMAN VH, KAPLAN G: Thalidomide as an anti-TNF-a inhibitor: implications for clinical use. Clin. Immunol Immunopathol (1996) 81(3):219–223.
   PubMedGoogle Scholar
• •Short review covering role of TNF-a in HIV-1 infection.
   Google Scholar
• CHAMBERS RJ, MARFAT A, CHENG JB etal.: Biarylcarbox-amide inhibitors of phosphodiesterase IV and tumor necrosis factor-a. Bioorg. Med. Chem. Letters (1997) 7(6):739–744.
   Google Scholar
• KLEINMAN EF, CAMPBELL E, GIORDANO LA et al.: Striking effect of hydroxamic acid substitution on the phos-phodiesterase Type 4 (PDE4) and TNFa inhibitory activity of two series of rolipram analogues: implica-tions for a new active site model of PDE4. J. Med. Chem. (1998) 41:266–270.
   PubMed Web of Science ®Google Scholar
• •First attempt to model the PDE4 catalytic site, based on highly potent PDE4/TNF-a inhibitors.
   Google Scholar
• COHAN VL, SHO WELL HJ, FISHER DA et al.: In vitro phar-macology of the novel phosphodiesterase Type 4 in-hibitor, CP-80633. J. Pharmacol. Exp. Ther. (1996) 278(3):1356–1361.
   PubMedGoogle Scholar
• BARNETTE MS, CHRISTENSEN SB, ESSAYAN, DM et al: SB207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti- inflammatory actions. J. Pharmacol. Exp. Ther. (1998) 284(0:420–426.
   PubMedGoogle Scholar
• MANABE H, AKUTA K, SEJIMO H et al.: Anti-inflammatory and bronchodilator properties of KF19514, a phosphodiesterase 4 and 1 inhibitor. Eur. J. Pharmacol. (1997), 332:97–107.
   PubMed Web of Science ®Google Scholar
• MOHLER KM, SLEATH PR, FITZNER JN et al. Protection against a lethal dose of endotoxin by an inhibitor of tu-mour necrosis factor processing. Nature (1994) 370(6486)218–220.
   Google Scholar
• GEARING AJ, BECKETT P, CHRISTODOULOU M et al: Processing of tumour necrosis factor-a precursor by metalloproteinases. Nature (1994) 370(6490)555–557.
   Google Scholar
• •A good initial description of TNF-a processing by MMPs.
   Google Scholar
• MCGEEHAN GM, BECHERER JD, BAST RC, Jr. et al.: Regula-tion of tumour necrosis factor-a processing by a metal-loproteinase inhibitor. Nature (1994) 370(6490) :558–561.
   Google Scholar
• GEARING AJH, BECKETT P, CHRISTODOULOU M et al: Matrix metalloproteinases and processing of pro-TNF-a. j Leukoc. Biol. (1995) 57:774–777.
   PubMed Web of Science ®Google Scholar
• MOSS ML, JIN S-LC, BECHERER et al: Structural features and biochemical properties of TNF-a converting en-zyme (TACE). j Neuroimmunol (1997) 72:127–129.
   PubMed Web of Science ®Google Scholar
• BLACK RA, RAUCH CT, KOZLOSKY CJ et al: A metallopro-teinase disintegrin that releases tumour-necrosis fac-tor-a from cells. Nature (1997) 385:729–733.
   PubMed Web of Science ®Google Scholar
• •First description of TACE purification and cloning.
   Google Scholar
• MOSS ML, JIN S-LC, MILLA ME et al: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-a. Nature (1997) 385:733–736.
   PubMed Web of Science ®Google Scholar
• •First description of TACE purification and cloning.
   Google Scholar
• CROWE PD, WALTER BN, MOHLER KM et al.: A metallo-proteinase inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J. Exp. Med. (1995) 181:1205–1210.
   PubMed Web of Science ®Google Scholar
• MULLBERG J, RAUCH CT, WOLFSON MF et al: Furtherevidence for a common mechanism for shedding of cell surface proteins. FEBS Lett. (1997) 401:235–238.
   PubMed Web of Science ®Google Scholar
• BECKETT RP, DAVIDSON AH, DRUMMOND AH, HUXLEY P, WHITTAKER M: Recent advances in matrix metallo-proteinase inhibitor research. Drug Disc. Today (1996) 1(0:16–26.
   Google Scholar
• LEVY DE, EZRIN AM: Matrix metalloproteinase inhibi-tor drugs. In: Emerging Drugs (Volume 2). WC Bowman, JD Fitzgerald, JB Taylor (Eds.), Ashley Publications Ltd., London, UK (1997):205–230.
   Google Scholar
• WOJTOWICZ-PRAGA SM, DICKSON RB, HAWKINS MJ: Matrix metalloproteinase inhibitors. Invest. New Drugs (1997) 15:61–75.
   PubMed Web of Science ®Google Scholar
• WHITE AD, BOCAN TMA, BOXER PA, PETERSON JT, SCHRIER D: Emerging therapeutic advances for the de-velopment of second generation matrix metalloprote-inase inhibitors. Curr. Pharm. Design (1997) 3:45–58.
   Web of Science ®Google Scholar
• Batimastat. Drugs Future (1996) 21(12):1215–1220.
   Google Scholar
• BAXTER AD, BIRD J, BHOGAL R et al.: A novel series of matrix metalloproteinase inhibitors for the treatment of inflammatory disorders. Bioorg. Med. Chem. Lett. (1997) 7(7)897–902.
   Google Scholar
• BAXTER AD, BHOGAL R, BIRD JB et al: Mercaptoacyl ma-trix metalloproteinase inhibitors: the effect of substi-tution at the mercaptoacyl moiety. Bioorg. Med. Chem. Lett. (1997) 7(20:2765–2770.
   Google Scholar
• HATTORI K, HIRANO T, USHIYAMA C et al.: A metallo-proteinase inhibitor prevents lethal acute graft-ver-sus-host disease in mice. Blood (1997) 90(2):542–548.
   PubMed Web of Science ®Google Scholar
• BLOXHAM DP: Therapeutic applications of anti-TNF monoclonal antibodies. Exp. Opin. Invest. Drugs (1994) 3 (9) :907–912.
   Google Scholar
• •A good overview of the use of antibodies in clinical trials.
   Google Scholar
• VAN DULLEMEN HM, VAN DEVENTER SJ, HOMMES DW et al: Treatment of Crohn's disease with anti-tumor ne-crosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 109 (0 :129–135.
   PubMedGoogle Scholar
• VAN DEVENTER SJH, CAMOGLIO L: Monoclonal anti-body therapy of inflammatory bowel disease. Pharm. World Sci. (1997) 19(2):55–59.
   PubMedGoogle Scholar
• ELLIOTT MJ, WOO P, CHARLES P et al: Suppression of fe-ver and the acute- phase response in a patient with ju-venile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-a (cA2). Br. J. Rheu-matol. (1997) 36(5):589–593.
   PubMedGoogle Scholar
• DAVIS D, CHARLES PJ, POTTER A et al.: Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. Br. J. Rheu-matol. (1997) 36(9):950–956.
   PubMedGoogle Scholar
• RANKIN EC, CHOY EH, KASSIMOS D et al.: The therapeu-tic effects of an engineered human anti-tumour necro-sis factor a antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol (1995) 34(4):334–342.
   PubMedGoogle Scholar
• DHAINAUT JF, VINCENT JL, RICHARD C et al.: CDP571, ahumanized antibody to tumor necrosis factor-a: safety, pharmacokinetics, immune response, and in-fluence of the antibody on cytokine concentrations in patients with septic shock. CDP571 sepsis study group. Grit. Care Med. (1995) 23(9):1461–1469.
   Google Scholar
• STACK WA, MANN SD, ROY AJ et al.: Randomised con-trolled trial of CDP571 antibody to tumour necrosis factor-a in Crohn's disease. Lancet (1 9 9 7) 349(9050521–524.
   Google Scholar
• HOLLER E, KOLB HJ, MITTERMULLER J et al.: Modulation of acute graft- versus-host-disease after allogenic bone marrow transplantation by tumor necrosis factor a(TNFa) release in the course of pretransplant condi-tioning: role of conditioning regimens and prophylac-tic application of a monoclonal antibody neutralizing human TNFa (MAK 195F). Blood (1995) 86(3):890–899.
   PubMed Web of Science ®Google Scholar
• PALEOLOG E: Target effector role of vascular endothe-IMm in the inflammatory response: insights from the clinical trial of anti-TNFa antibody in rheumatoid ar-thritis. J. Clin. Pathol Mol Pathol. (1997) 50:225–233.
   Web of Science ®Google Scholar
• •Detailed review of the role of TNF in inflammatory disease.
   Google Scholar
• WALLACH D: Cell death induction by TNF: a matter of self control. Trends Biochem. Sci. (1997) 22:107–109.
   PubMed Web of Science ®Google Scholar
• BOLDIN MP, METT IL, VARFOLOMEEV EE et al. Self-association of the 'death domains' of the p55 tumor ne-crosis factor (TNF) receptor and Fas/AP01 prompts signaling for TNF and Fas/AP01 effects. (1995) 270(1)387–391.
   Google Scholar
• TERLIZZESE M, SIMONI P, ANTONETTI F: In vitro com-parison of inhibiting ability of soluble TNF receptor p75 (TBP II) vs. soluble TNF receptor p55 (TBP 0 against TNF-a and TNF-13. J. Interferon Cytokine Res. (1996) 16:1047–1053.
   PubMed Web of Science ®Google Scholar
• LEACH SD, GORELICK S, MODLIN IM: New perspectives on acute pancreatitis. Scan. J. Gastroenterol. Stipp]. (1992) 192:29–38.
   PubMedGoogle Scholar